Salmeterol/fluticasone propionate - Neothetics

Drug Profile

Salmeterol/fluticasone propionate - Neothetics

Alternative Names: Fluticasone propionate/salmeterol - Neothetics; LIPO-102; Salmeterol xinafoate/fluticasone propionate - Lithera; Salmeterol xinafoate/fluticasone propionate - Neothetics

Latest Information Update: 28 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lithera
  • Developer Neothetics
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eye disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Exophthalmos
  • Discontinued Subcutaneous fat disorders

Most Recent Events

  • 31 Dec 2016 Neothetics has patent protection for Salmeterol/fluticasone propionate in USA and other countries
  • 31 Mar 2015 Phase II development is ongoing in Exophthalmos in Australia and New Zealand
  • 31 Mar 2015 Discontinued - Phase-II for Subcutaneous fat disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top